Synergism/complementarity of recombinant adenoviral vectors and other vaccination platforms during induction of protective immunity against malaria
The lack of immunogenicity of most malaria antigens and the complex immune responses required for achieving protective immunity against this infectious disease have traditionally hampered the development of an efficient human malaria vaccine. The current boom in development of recombinant viral vect...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Fundação Oswaldo Cruz (FIOCRUZ)
2011-08-01
|
| Series: | Memorias do Instituto Oswaldo Cruz |
| Subjects: | |
| Online Access: | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0074-02762011000900024&lng=en&tlng=en |
| _version_ | 1797712684499599360 |
|---|---|
| author | Ana Paula Morais Martins Almeida Oscar Bruna-Romero |
| author_facet | Ana Paula Morais Martins Almeida Oscar Bruna-Romero |
| author_sort | Ana Paula Morais Martins Almeida |
| collection | DOAJ |
| description | The lack of immunogenicity of most malaria antigens and the complex immune responses required for achieving protective immunity against this infectious disease have traditionally hampered the development of an efficient human malaria vaccine. The current boom in development of recombinant viral vectors and their use in prime-boost protocols that result in enhanced immune outcomes have increased the number of malaria vaccine candidates that access pre-clinical and clinical trials. In the frontline, adenoviruses and poxviruses seem to be giving the best immunization results in experimental animals and their mutual combination, or their combination with recombinant proteins (formulated in adjuvants and given in sequence or being given as protein/virus admixtures), has been shown to reach unprecedented levels of anti-malaria immunity that predictably will be somehow reproduced in the human setting. However, all this optimism was previously seen in the malaria vaccine development field without many real applicable results to date. We describe here the current state-of-the-art in the field of recombinant adenovirus research for malaria vaccine development, in particular referring to their use in combination with other immunogens in heterologous prime-boost protocols, while trying to simultaneously show our contributions and point of view on this subject. |
| first_indexed | 2024-03-12T07:25:21Z |
| format | Article |
| id | doaj.art-96e1aaa3fdd04994830d7cd5aec391ff |
| institution | Directory Open Access Journal |
| issn | 1678-8060 |
| language | English |
| last_indexed | 2024-03-12T07:25:21Z |
| publishDate | 2011-08-01 |
| publisher | Fundação Oswaldo Cruz (FIOCRUZ) |
| record_format | Article |
| series | Memorias do Instituto Oswaldo Cruz |
| spelling | doaj.art-96e1aaa3fdd04994830d7cd5aec391ff2023-09-02T22:11:04ZengFundação Oswaldo Cruz (FIOCRUZ)Memorias do Instituto Oswaldo Cruz1678-80602011-08-01106suppl 119320110.1590/S0074-02762011000900024S0074-02762011000900024Synergism/complementarity of recombinant adenoviral vectors and other vaccination platforms during induction of protective immunity against malariaAna Paula Morais Martins Almeida0Oscar Bruna-Romero1Universidade Federal de Minas GeraisUniversidade Federal de Minas GeraisThe lack of immunogenicity of most malaria antigens and the complex immune responses required for achieving protective immunity against this infectious disease have traditionally hampered the development of an efficient human malaria vaccine. The current boom in development of recombinant viral vectors and their use in prime-boost protocols that result in enhanced immune outcomes have increased the number of malaria vaccine candidates that access pre-clinical and clinical trials. In the frontline, adenoviruses and poxviruses seem to be giving the best immunization results in experimental animals and their mutual combination, or their combination with recombinant proteins (formulated in adjuvants and given in sequence or being given as protein/virus admixtures), has been shown to reach unprecedented levels of anti-malaria immunity that predictably will be somehow reproduced in the human setting. However, all this optimism was previously seen in the malaria vaccine development field without many real applicable results to date. We describe here the current state-of-the-art in the field of recombinant adenovirus research for malaria vaccine development, in particular referring to their use in combination with other immunogens in heterologous prime-boost protocols, while trying to simultaneously show our contributions and point of view on this subject.http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0074-02762011000900024&lng=en&tlng=enmalaria vaccinesPlasmodium vivaxPlasmodium falciparumAdenoviridaeimmunization schedule |
| spellingShingle | Ana Paula Morais Martins Almeida Oscar Bruna-Romero Synergism/complementarity of recombinant adenoviral vectors and other vaccination platforms during induction of protective immunity against malaria Memorias do Instituto Oswaldo Cruz malaria vaccines Plasmodium vivax Plasmodium falciparum Adenoviridae immunization schedule |
| title | Synergism/complementarity of recombinant adenoviral vectors and other vaccination platforms during induction of protective immunity against malaria |
| title_full | Synergism/complementarity of recombinant adenoviral vectors and other vaccination platforms during induction of protective immunity against malaria |
| title_fullStr | Synergism/complementarity of recombinant adenoviral vectors and other vaccination platforms during induction of protective immunity against malaria |
| title_full_unstemmed | Synergism/complementarity of recombinant adenoviral vectors and other vaccination platforms during induction of protective immunity against malaria |
| title_short | Synergism/complementarity of recombinant adenoviral vectors and other vaccination platforms during induction of protective immunity against malaria |
| title_sort | synergism complementarity of recombinant adenoviral vectors and other vaccination platforms during induction of protective immunity against malaria |
| topic | malaria vaccines Plasmodium vivax Plasmodium falciparum Adenoviridae immunization schedule |
| url | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0074-02762011000900024&lng=en&tlng=en |
| work_keys_str_mv | AT anapaulamoraismartinsalmeida synergismcomplementarityofrecombinantadenoviralvectorsandothervaccinationplatformsduringinductionofprotectiveimmunityagainstmalaria AT oscarbrunaromero synergismcomplementarityofrecombinantadenoviralvectorsandothervaccinationplatformsduringinductionofprotectiveimmunityagainstmalaria |